Company Overview
Snapshot
Founded in September 2008 by Liron Elia, ART Medical operates with 51–200 employees. The company has raised $82.3M across 6 funding rounds from 3 investors. In July 2023, a new clinical study demonstrated unprecedented results for ART Medical's smART+ platform, showing significant reductions in ICU length of stay and ventilation days, alongside improved feeding efficacy.
Business overview
ART Medical is a Health Tech & Life Sciences company focused on critical care, developing an all-in-one nutrition management platform. Its core product, smART+, is a sensor-based feeding tube designed to detect and prevent feeding-related complications such as aspiration pneumonia, ventilator-associated events, malnutrition, and acute kidney injury. The company leverages artificial intelligence and sensing technologies to personalize ICU care and serves the healthcare provider market in the United States and Israel.
Strategic signal
ART Medical's partnership with Teva Israel in March 2023 to bring its technology to critical care units signals a significant market expansion and validation of its solutions. This collaboration indicates a strategic move to broaden the reach of its life-saving technology, suggesting increased adoption and impact within the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- What is ART Medical's primary focus?
- ART Medical focuses on critical care, developing an all-in-one solution designed to detect and prevent feeding-related complications while ensuring optimal patient nutrition to accelerate recovery.
- What is the smART+ platform?
- smART+ is ART Medical's sensor-based feeding tube designed to detect and prevent reflux events, aiming to reduce ICU-acquired complications like aspiration pneumonia and malnutrition.
- Has ART Medical received FDA approval for its technology?
- Yes, ART Medical's technology has received FDA approval, and the company continues to expand its technology and work on clinical validations.
- What were the findings of the clinical study on smART+ in July 2023?
- A clinical study in July 2023 showed unprecedented results for ART Medical's smART+ platform, including a significant reduction in length of stay and ventilation days in the ICU, as well as improved feeding efficacy.
- What strategic partnership did ART Medical announce in March 2023?
- In March 2023, ART Medical announced a partnership with Teva Israel to bring its technology to critical care units, aiming to expand the reach of its solutions.